Gateway for:

Member Countries

Prophylaxis of Hemolytic Disease of Newborn

#3274


Obtaining and Application of Anti-Rhesus Monoclonal Immunoglobulin G (anti-D) for Prophylaxis of Hemolytic Disease of Newborn

Tech Area / Field

  • BIO-IND/Industrial Biotechnology/Biotechnology
  • MED-DRG/Drug Discovery/Medicine

Status
3 Approved without Funding

Registration date
29.04.2005

Leading Institute
Hematolog LTD, Russia, Moscow

Supporting institutes

  • Institute of Immunological Engineering, Russia, Moscow reg., Lyubuchany

Collaborators

  • ViroGen Corp., USA, MA, Watertown

Project summary

Polyclonal immunoglobulin G (anti-D) is used for prophylaxis of hemolytic disease of newborn in rhesus-incompatible pregnancy. Primary purpose of the project is connected with low supply of polyclonal anti-D all over the world, and in Russia particularly, its deficiency is so high, that the need for prophylaxis is satisfied only by 8-10%. We have obtained monoclonal anti-D antibodies, but their high prophylactic activity is still under a question. At the same time using a combination of 20% polyclonal anti-D with the obtained monoclonal antibodies, complete prophylactic activity has been determined. Thus, the organization of manufacturing of such combined preparation may increase possible anti-D immunoglobulin production 5-fold. However, before launching of a large-scale production, the studies in human donors in order to detect the active component of the polyclonal immunoglobulin enhancing the effect of the monoclonal preparation might be performed. Such component (an unknown antibody) could possibly be detected and obtained biotechnologically providing anti-D immunoglobulin production with unlimited quantity of primary products.


Back